Hellenic National Center for Research, Prevention and Treatment of Diabetes Mellitus and its Complications (HNDC), Athens, Greece.
Eur J Endocrinol. 2010 Oct;163(4):625-30. doi: 10.1530/EJE-10-0246. Epub 2010 Jul 19.
Although clinical hyperthyroidism (HR) is associated with insulin resistance, the information on insulin action in subclinical hyperthyroidism (SHR) is limited.
To investigate this, we assessed the sensitivity of glucose metabolism to insulin in vivo (by an oral glucose tolerance test) and in vitro (by measuring insulin-stimulated rates of glucose transport in isolated monocytes) in 12 euthyroid subjects (EU), 16 patients with HR, and 10 patients with SHR.
HR and SHR patients displayed higher postprandial glucose levels (area under the curve, AUC(0)(-)(300) 32,190±1067 and 31,497±716,mg/dl min respectively) versus EU (27,119±1156 mg/dl min, P<0.05). HR but not SHR patients displayed higher postprandial insulin levels (AUC(0)(-)(300) 11,020±985 and 9565±904 mU/l min respectively) compared with EU subjects (AUC(0)(-)(300) 7588±743 mU/l min, P<0.05). Homeostasis model assessment index was increased in HR and SHR patients (2.81±0.3 and 2.43±0.38 respectively) compared with EU subjects (1.27±0.16, P<0.05), while Matsuda and Belfiore indices were decreased in HR (4.21±0.41 and 0.77±0.05 respectively, P<0.001) and SHR patients (4.47±0.33 and 0.85±0.05 respectively, P<0.05 versus EU (7.76±0.87 and 1 respectively). At 100 μU/ml insulin, i) GLUT3 levels on the monocyte plasma membrane were increased in HR (468.8±7 mean fluorescence intensity (MFI)) and SHR patients (522.2±25 MFI) compared with EU subjects (407±18 MFI, P<0.01 and P<0.05 respectively), ii) glucose transport rates in monocytes (increases from baseline) were decreased in HR patients (37.8±5%) versus EU subjects (61.26±10%, P<0.05).
Insulin-stimulated glucose transport in isolated monocytes of patients with HR was decreased compared with EU subjects. Insulin resistance was comparable in patients with both HR and SHR.
尽管临床甲状腺功能亢进症(HR)与胰岛素抵抗有关,但亚临床甲状腺功能亢进症(SHR)患者胰岛素作用的信息有限。
为了研究这一点,我们评估了 12 名甲状腺功能正常的受试者(EU)、16 名 HR 患者和 10 名 SHR 患者体内(通过口服葡萄糖耐量试验)和体外(通过测量胰岛素刺激的分离单核细胞中葡萄糖转运率)葡萄糖代谢对胰岛素的敏感性。
HR 和 SHR 患者的餐后血糖水平(AUC(0)(-)(300) 32,190±1067 和 31,497±716,mg/dl min 分别)高于 EU(AUC(0)(-)(300) 27,119±1156 mg/dl min,P<0.05)。与 EU 受试者相比,HR 患者的餐后胰岛素水平(AUC(0)(-)(300) 11,020±985 和 9,565±904 mU/l min 分别)更高(AUC(0)(-)(300) 7588±743 mU/l min,P<0.05)。HR 和 SHR 患者的稳态模型评估指数升高(分别为 2.81±0.3 和 2.43±0.38),而 EU 患者为 1.27±0.16(P<0.05),而 Matsuda 和 Belfiore 指数在 HR(分别为 4.21±0.41 和 0.77±0.05)和 SHR 患者中降低(分别为 4.47±0.33 和 0.85±0.05,P<0.001 和 P<0.05 与 EU(分别为 7.76±0.87 和 1)。在 100μU/ml 胰岛素时,i)HR(468.8±7 平均荧光强度(MFI))和 SHR 患者(522.2±25 MFI)的单核细胞膜上的 GLUT3 水平高于 EU 受试者(407±18 MFI,P<0.01 和 P<0.05),ii)单核细胞中的葡萄糖转运率(相对于基线的增加)在 HR 患者中降低(37.8±5%)与 EU 受试者(61.26±10%,P<0.05)。
与 EU 受试者相比,HR 患者的胰岛素刺激的单核细胞葡萄糖转运降低。HR 和 SHR 患者的胰岛素抵抗相当。